Background: The encapsulated follicular variant (EFV) of papillary thyroid carcinoma (PTC) is the most discussed entity in thyroid pathology. Recently, the question of whether or not EFV-PTC is a malignant entity has been the subject of renewed discussion in the light of recent molecular and clinical studies. The aim of this study was to analyze the malignancy ratios of each category of the Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) if EFV-PTC is no longer considered as a malignant entity. Materials and Methods: Data on thyroid fine-needle aspirations (n = 1,886) with surgical follow-up between 1999 and 2014 were studied. EFV-PTC cases constituted 27% (94/343) of the malignant cases. Results: Malignancy ratios were determined as nondiagnostic, benign, atypia/follicular lesion of undetermined significance, suspicious for follicular neoplasm/follicular neoplasm, suspicious for malignancy, and malignant categories of the TBSRTC in 13, 7, 45, 30, 72 and 98%, respectively. If EFV-PTC was not regarded as malignant, malignancy ratios would decrease to 6.5, 6, 30, 10, 48, and 87% for each category in the same order. Conclusions: The current study showed that the most significant decrease in relative malignancy ratios was seen in the suspicious for follicular neoplasm/follicular neoplasm category (66% relative decrease), but all categories represented a considerable decrease.

1.
Vigneri R, Malandrino P, Vigneri P: The changing epidemiology of thyroid cancer: why is incidence increasing? Curr Opin Oncol 2015;27:1-7.
2.
Pellegriti G, Frasca F, Regalbuto C, Squatrito S, Vigneri R: Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol 2013;2013:965212.
3.
Morris LG, Sikora AG, Tosteson TD, Davies L: The increasing incidence of thyroid cancer: the influence of access to care. Thyroid 2013;23:885-891.
4.
Baloch ZW, LiVolsi VA, Asa SL, Rosai J, Merino MJ, Randolph G, Vielh P, DeMay RM, Sidawy MK, Frable WJ: Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: a synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference. Diagn Cytopathol 2008;36:425-437.
5.
Cibas ES, Ali SZ: The Bethesda System for Reporting Thyroid Cytopathology. Thyroid 2009;19:1159-1165.
6.
Hazard JB, Crile G, Dinsmore RS, Hawk WA, Kenyon R: Neoplasms of the thyroid: classification, morphology, and treatment. AMA Arch Pathol 1955;59:502-513.
7.
Faquin WC, Baloch ZW: Fine-needle aspiration of follicular patterned lesions of the thyroid: diagnosis, management, and follow-up according to National Cancer Institute (NCI) recommendations. Diagn Cytopathol 2010;38:731-739.
8.
Faquin WC: The thyroid gland: recurring problems in histologic and cytologic evaluation. Arch Pathol Lab Med 2008;132:622-632.
9.
Ghossein R: Encapsulated malignant follicular cell-derived thyroid tumors. Endocr Pathol 2010;21:212-218.
10.
Rivera M, Ricarte-Filho J, Knauf J, Shaha A, Tuttle M, Fagin JA, Gosshein RA: Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns. Mod Pathol 2010;23:1191-2000.
11.
Armstrong MJ, Yang H, Yip L, Ohori NP, McCoy KL, Stang MT, Hodak SP, Nikiforova MN, Carty SE, Nikiforov YE: PAX8/PPARγ rearrangement in thyroid nodules predicts follicular-pattern carcinomas, in particular the encapsulated follicular variant of papillary carcinoma. Thyroid 2014;24:1369-1374.
12.
Ustun B, Chhieng D, Van Dyke A, Carling T, Holt E, Udelsman R, Adeniran AJ: Risk stratification in follicular neoplasm: a cytological assessment using the modified Bethesda classification. Cancer Cytopathol 2014;122:536-545.
13.
Yang GC, Fried K, Yakoushina TV, Schreiner AM: Encapsulated follicular variant of papillary thyroid carcinoma: fine-needle aspiration with ultrasound and histologic correlation of 41 cases. Acta Cytol 2013;57:26-32.
14.
Lee SR, Jung CK, Kim TE, Bae JS, Jung SL, Choi YJ, Kang CS: Molecular genotyping of follicular variant of papillary thyroid carcinoma correlates with diagnostic category of fine-needle aspiration cytology: values of RAS mutation testing. Thyroid 2013;23:1416-1422.
15.
Hunt JL, Dacic S, Barnes EL, Bures JC: Encapsulated follicular variant of papillary thyroid carcinoma. Am J Clin Pathol 2002;118:602-603; author reply 605-606.
16.
Gupta S, Ajise O, Dultz L, Wang B, Nonaka D, Ogilvie J, Helle KS, Patel KN: Follicular variant of papillary thyroid cancer: encapsulated, nonencapsulated, and diffuse: distinct biologic and clinical entities. Arch Otolaryngol Head Neck Surg 2012;138:227-233.
17.
Ganly I, Wang L, Tuttle RM, Katabi N, Ceballos GA, Harach HR, Ghossein R: Invasion rather than nuclear features correlates with outcome in encapsulated follicular tumors: further evidence for the reclassification of the encapsulated papillary thyroid carcinoma follicular variant. Hum Pathol 2015;46:657-664.
18.
Faquin WC, Wong LQ, Afrogheh AH, Ali SZ, Bishop JA, Bongiovanni M, Pusztaszeri MP, VandenBussche CJ, Gourmaud J, Vaickus LJ, Baloch ZW: Impact of reclassifying noninvasive follicular variant of papillary thyroid carcinoma on the risk of malignancy in The Bethesda System for Reporting Thyroid Cytopathology. Cancer Cytopathol 2016;124:181-187.
19.
Nikiforov YE, Seethala RR, Tallini G, Baloch ZW, Basolo F, Thompson LD, Barletta JA, Wenig BM, Al Ghuzlan A, Kakudo K, Giordano TJ, Alves VA, Khanafshar E, Asa SL, El-Naggar AK, Gooding WE, Hodak SP, Lloyd RV, Maytal G, Mete O, Nikiforova MN, Nosé V, Papotti M, Poller DN, Sadow PM, Tischler AS, Tuttle RM, Wall KB, LiVolsi VA, Randolph GW, Ghossein RA: Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment of indolent tumors. JAMA Oncol DOI: 10.1001/2016.0386.
20.
Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L: 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016;26:1-133.
21.
Wu HH, Rose C, Elsheikh TM: The Bethesda System for Reporting Thyroid Cytopathology: an experience of 1,382 cases in a community practice setting with the implication for risk of neoplasm and risk of malignancy. Diagn Cytopathol 2012;40:399-403.
22.
Deniwar A, Hambleton C, Thethi T, Moroz K, Kandil E: Examining the Bethesda criteria risk stratification of thyroid nodules. Pathol Res Pract 2015;211:345-348.
23.
Bose S, Walts AE: Thyroid fine needle aspirate: a post-Bethesda update. Adv Anat Pathol 2012;19:160-169.
24.
Mete O, Asa SL: Precursor lesions of endocrine system neoplasms. Pathology 2013;45:316-330.
25.
Vivero M, Kraft S, Barletta JA: Risk stratification of follicular variant of papillary thyroid carcinoma. Thyroid 2013;23:273-279.
26.
Walts AE, Mirocha JM, Bose S: Follicular variant of papillary thyroid carcinoma (FVPTC): histological features, BRAF V600E mutation, and lymph node status. J Cancer Res Clin Oncol 2015;141:1749-1756.
27.
Hazard JB, Crile G Jr, Dinsmore RS, Hawk WA, Kenyon R: Neoplasms of the thyroid gland: anatomical and clinical review (in Portuguese). Resen Clin Cient 1955;24:79-82.
28.
Schmid KW, Farid NR: How to define follicular thyroid carcinoma? Virchows Arch 2006;448:385-393.
29.
Baloch ZW, LiVolsi VA: Encapsulated follicular variant of papillary thyroid carcinoma with bone metastases. Mod Pathol 2000;13:861-865.
30.
Rivera M, Ricarte-Filho J, Patel S, Tuttle M, Shaha A, Shah JP, Fagin JA, Ghossein RA: Encapsulated thyroid tumors of follicular cell origin with high grade features (high mitotic rate/tumor necrosis): a clinicopathologic and molecular study. Hum Pathol 2010;41:172-180.
31.
Rosario PW, Penna GC, Calsolari MR: Noninvasive encapsulated follicular variant of papillary thyroid carcinoma: is lobectomy sufficient for tumours ≥1 cm? Clin Endocrinol (Oxf) 2014;81:630-632.
32.
Strickland KC, Howitt BE, Marqusee E, Alexander EK, Cibas ES, Krane JF, Barletta JA: The Impact of noninvasive follicular variant of papillary thyroid carcinoma on rates of malignancy for fine-needle aspiration diagnostic categories. Thyroid 2015;25:987-992.
33.
Baloch ZW, LiVolsi VA: Follicular-patterned afflictions of the thyroid gland: reappraisal of the most discussed entity in endocrine pathology. Endocr Pathol 2014;25:12-20.
34.
LiVolsi VA, Baloch ZW: Follicular-patterned tumors of the thyroid: the battle of benign vs. malignant vs. so-called uncertain. Endocr Pathol 2011;22:184-189.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.